AstraZeneca AZN and Japan-based partner Daiichi Sankyo announced that the FDA has accepted a supplemental biologics license ...

Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for the ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing ...

AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...

ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive ...

The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults ...

Cambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review b ...

(Alliance News) - Daiichi Sankyo Co Ltd and AstraZeneca PLC on Wednesday said the US Food & Drug Administration has granted priority review for Enhertu in combination with pertuzumab as a first-line ...

Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC) ...

Datroway showed a confirmed 45% response rate in treated EGFR-mutant non-small cell lung cancer patients. The median duration of response was 6.5 months in TROPION-Lung trials. Get the data-driven ...

Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for ...